Imagenetix: NIKKEN's Attempt To Invalidate Patent Fails

The United States Patent & Trademark Office (USPTO) Confirms The Validity of Imagenetix's Patent No. 5,569,676 (Cetyl Myristoleate)

Dec 11, 2013, 18:07 ET from Imagenetix, Inc.

SAN DIEGO, Dec. 11, 2013 /PRNewswire/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGXQ), announced today that the Board of Appeals for the United States Patent & Trade Office (USPTO) rejected NIKKEN's effort to invalidate Imagenetix's patent no. 5,569,676 and issued a decision confirming the validity of the patent. On November 27, 2013, Imagenetix requested that its case against NIKKEN be reinstated. In this suit, which was originally filed on April 29, 2011, Imagenetix seeks damages for NIKKEN's willful infringement of Imagenetix's patent.

In response to Imagenetix's lawsuit, NIKKEN sought for the USPTO to invalidate Imagenetix's patent through the agency's re-examination process. Following a patent examiner's initial determination of the patent, NIKKEN prematurelyand incorrectlyissued a press release (on January 12, 2012) stating the following: "The United States Patent Office (USPTO) re-examined Imagenetix's patent No. 5,569,676 and rendered its final decision, rejecting Imagenetix's patent claim."  Now that the USPTO has issued its final decision confirming the validity of the patent, NIKKEN has not yet issued a correcting press release notifying its distributors or others of the agency's decision.

William P. Spencer, President of Imagenetix, stated: "I am delighted that the USPTO confirmed the validity of Imagenetix's patent. We were always confident in the merits of our patent, and we will continue to actively prosecute ongoing infringement of the patent."

About Imagenetix Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates proprietary over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners.

Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected. Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company's SEC filings.


Imagenetix Investor Relations

William P. Spencer


Chief Executive Officer

Imagenetix, Inc.

Tel: (858) 674-8455

SOURCE Imagenetix, Inc.